Renaissance Capital logo

Genelux Filed Terms, Nasdaq: GNLX

Phase 3 biotech developing oncolytic viral immunotherapies for solid tumors.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We have met the preestablished endpoint for our Phase 2 clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Employing our proprietary selection technology and discovery and development platform (CHOICE), we have developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. These provide potential utility in multiple tumor types in both the monotherapy and combination therapy settings, via physician-preferred administration techniques, including regional (e.g., intraperitoneal) and systemic (e.g., intravenous) delivery routes.
more less
IPO News for Genelux
more
IPO Data
IPO File Date 06/24/2022
Offer Price
Price Range $6.00 - $7.00
Offer Shares (mm) 2.5
Deal Size ($mm) $16
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $6.00 - $7.00
Offer Shares (mm) 2.5
Deal Size ($mm) $16
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Westlake Village, CA
Founded 2001
Employees 14
Website www.genelux.com